New Developments in the Diagnosis
and Treatment of Psoriatic Arthritis
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in
the live session, you are not eligible for continuing education
credits from this archive.
This activity is valid from January 10, 2018 to January 31, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
AbbVie and Lilly USA LLC
Psoriatic arthritis is a debilitating, progressive, inflammatory
disease that is associated with a number of dermatologic and
musculoskeletal manifestations that affect men and women equally.
Patients often experience extreme pain and joint damage which affect
their quality of life, physical function, and ability to work.
Approximately 30% to 40% of people with psoriasis will also develop
psoriatic arthritis, a painful and potentially disfiguring condition
that remains underdiagnosed. Symptoms include fatigue, joint
inflammation, and potentially progressive joint damage. Diagnosis
may be easier to confirm if psoriasis coexists with symptoms of
arthritis. However, in as many as 15% of cases, symptoms of
psoriatic arthritis appear before symptoms of psoriasis. A careful
medical history, physical examination, blood tests, magnetic
resonance imaging (MRI), and x-rays of the involved joints along
with a dermatologic evaluation may be used to diagnose psoriatic
arthritis. In addition to early diagnosis, the goal of treatment for
psoriatic arthritis is to properly manage the disease by obtaining
remission; which includes prompt, aggressive treatment aimed at
limiting joint damage and clearing skin psoriasis. Nonsteroidal
anti-inflammatory drugs (NSAIDs) and traditional disease-modifying
antirheumatic drugs (DMARDs) are used to reduce inflammation caused
by arthritis with the intent of reducing pain, swelling and
stiffness. However, many of these medications suppress the immune
system and lead to a potential increase risk of infections.
Thankfully novel biologic treatments have been developed and have
been proven to stop joint damage as well as pain and swelling in
moderate to severe psoriatic arthritis.
Upon Completion of this
activity, participants will be able to:
Explore the safety and efficacy of
current and emerging treatments, including the mechanism of
action of newer biologics
Assess the latest developments in
screening tools that identify patients at risk for psoriatic
Identify the common comorbidities in
patients with psoriatic arthritis
Analyze strategies on how effective
systematic therapies might be used in clinical practice
Discuss the latest research
developments and guidelines in the management of psoriatic
||Atul Deodhar, MD, MRCP
Professor of Medicine
Oregon Health & Science University
OHSU Division of Arthritis & Rheumatic Diseases
serves as an advisor or consultant for Eli Lilly,
Janssen, Novartis, Pfizer and UCB. He receives grants
for clinical research from Amgen, AbbVie, Eli Lilly,
Janssen, Novartis, Pfizer and UCB. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by educational grants from
AbbVie and Lilly USA LLC
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue